Granisym

Granisym is an oral, prescription medication that contains the active ingredient granisetron, a 5-HT3 receptor antagonist used in the European market. It belongs to the antiemetic therapeutic class and works by blocking serotonin receptors in the central and peripheral nervous system to reduce nausea and vomiting associated with chemotherapy and surgery.

Granisym is prescribed to manage nausea and vomiting in specific clinical settings. It is commonly used for:

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Adjunct therapy in patients receiving highly emetogenic chemotherapy. - Situations where other antiemetics are insufficient or contraindicated. - Supportive care for patients experiencing radiation‑induced nausea.

Granisym may cause a range of side effects, most of which are mild and transient.

Common: - Headache - Constipation - Fatigue - Dizziness - Diarrhea - Abdominal discomfort

Serious: - Severe allergic reaction (rash, swelling, difficulty breathing) - Cardiac arrhythmia or QT prolongation - Persistent severe constipation or bowel obstruction - Hepatic dysfunction indicated by abnormal liver enzymes

Before starting Granisym, certain precautions should be considered. Patients and clinicians should be aware of: - Known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Pre‑existing cardiac conditions, especially those affecting QT interval. - Severe hepatic impairment, which may require dose adjustment. - Pregnancy and breastfeeding status, as safety data are limited. - Concomitant use of other medications that may prolong the QT interval. - Monitoring for signs of severe constipation or bowel obstruction.

Granisym can interact with other drugs, influencing its safety and effectiveness.

Avoid: - Other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). - Strong CYP3A4 inhibitors that may increase granisetron levels.

Use with caution: - CYP3A4 inducers such as rifampin, which may reduce efficacy. - Drugs that also affect serotonin pathways (e.g., SSRIs, tramadol) due to additive effects. - Medications causing electrolyte disturbances that can exacerbate QT prolongation. - Concurrent use of other antiemetics, requiring dose adjustments.